Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) is a healthcare technology company focused on intelligent medication management, and the OMCL news page on Stock Titan aggregates company-specific updates that matter to investors and healthcare observers. Omnicell describes itself as a leader in transforming the pharmacy and nursing care delivery model, with solutions that combine automation, AI-enabled intelligence, and expert services to support clinical, operational, and financial outcomes across all settings of care.
News related to Omnicell often centers on financial results, product innovation, and strategic developments. The company regularly issues earnings releases and guidance updates, discussing performance across categories such as connected devices, technical services, SaaS and Expert Services, and consumables. Press releases also cover events like conference presentations, investor Q&A sessions, and participation in industry meetings, providing context on how management communicates its strategy and outlook.
Product and technology announcements are another key theme in OMCL news. Examples include the launch of Omnicell Titan XT, an enterprise automated dispensing system powered by the OmniSphere cloud platform, and updates on OmniSphere certifications and capabilities. Omnicell also highlights initiatives such as specialty pharmacy services, URAC Health Care Management Certification, and innovation-focused events like Omnicell Illuminate and the IV TRUST Summit, which showcase developments in robotics, smart devices, software workflows, and data and analytics.
By following OMCL news, readers can monitor how Omnicell advances its vision of autonomous medication management, how it positions its solutions for health systems, retail and specialty pharmacies, and how management addresses risks and opportunities in a regulated healthcare environment. The Stock Titan news feed helps users track these announcements in one place for ongoing reference.
Omnicell, Inc. (Nasdaq:OMCL), a prominent provider of medication management solutions, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 9:00 a.m. ET. The presentation will feature Randall Lipps, Chairman, President, and CEO, alongside CFO Peter Kuipers. Interested parties can access live and archived webcasts on the Omnicell website. Omnicell has been dedicated to improving pharmacy care delivery since 1992, focusing on enhancing patient safety and operational efficiency through innovative technologies.
Omnicell reported third-quarter 2022 revenues of $348 million, reflecting a 17% increase year-over-year, yet faced profit declines. GAAP net income dropped to $17 million ($0.37 per diluted share), down from $29 million ($0.61) in Q3 2021. Non-GAAP net income was $45 million ($1.00 per diluted share), down from $50 million ($1.08). The company lowered its 2022 guidance amid capital budget freezes, expecting total revenues between $1.284 billion to $1.294 billion. Despite near-term challenges, Omnicell remains confident in its long-term strategy.
Omnicell, Inc. (Nasdaq:OMCL) will announce its Q2 2022 financial results on November 2, 2022, before the market opens. Following the announcement, a conference call and webcast are scheduled for 8:30 a.m. ET. The event will be accessible to the public via phone and through Omnicell’s Investor Relations website.
Founded in 1992, Omnicell focuses on enhancing medication management and adherence in healthcare, aiming to reduce costs and improve outcomes with its technology-driven services.
Omnicell, Inc. has launched its Specialty Pharmacy Services, a new solution aimed at enhancing medication management for health systems and pharmacies. This initiative addresses the projected $316 billion specialty drug market by 2025, focusing on improving patient care and financial outcomes through a comprehensive service model. The offering aims to help hospitals establish and optimize specialty pharmacy operations, enhancing access to medications and driving revenue. With the rapid rise of chronic illnesses, Omnicell's services are timely in addressing healthcare demands.
Omnicell, Inc. (NASDAQ: OMCL) held its 2022 Investor Day, highlighting its transformation to an Advanced Services business model aimed at achieving long-term growth. The company anticipates this model will represent 20% to 30% of total revenue by 2025, targeting $1.9 billion to $2.0 billion in revenue with a 14% to 15% CAGR. Omnicell boasts a $90 billion+ total addressable market and partnerships with major health systems. The event reaffirmed its focus on ESG strategies and disciplined execution for sustainable, profitable growth.
Omnicell, Inc. (Nasdaq:OMCL), a leader in medication management solutions, announced participation in the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 1:55 p.m. ET. Scott Seidelmann, Executive VP and Chief Commercial Officer, will present.
Webcasts will be available live and archived on Omnicell's website. Founded in 1992, Omnicell aims to enhance pharmacy care delivery through automation and technology, impacting facilities across North America, the UK, Germany, and Australia. For more information, visit www.omnicell.com.
Omnicell will host an Investor Day on September 20, 2022, at 1:00 p.m. Eastern Time. The event will feature presentations from the executive leadership team discussing the company’s unique business strategy and long-term financial outlook, followed by a Q&A session. Speakers include CEO Randall Lipps, CFO Peter Kuipers, CCO Scott Seidelmann, and SVP Danny Sanchez. A live webcast will be available on Omnicell's website, and a replay will follow the event.
Omnicell, listed on NASDAQ under the symbol OMCL, focuses on enhancing medication management to improve patient outcomes.
Omnicell, Inc. (NASDAQ:OMCL) reported Q2 2022 GAAP revenues of $331 million, a 22% increase year-over-year, despite a modest impact from a ransomware incident. GAAP net income was $9 million or $0.20 per diluted share, down from $20 million or $0.43 a year ago. Non-GAAP revenues also rose to $332 million, with non-GAAP net income at $38 million or $0.84 per diluted share, compared to $44 million or $0.97 previously. The company reaffirmed its full-year guidance, expecting revenues between $1.385 billion and $1.410 billion.
Omnicell, Inc. (NASDAQ: OMCL) will announce its Q2 2022 financial results on August 4, 2022, after market hours. The company will conduct a conference call at 1:30 p.m. PT to discuss the results. Omnicell specializes in medication management and adherence solutions aimed at improving healthcare outcomes and reducing costs. As a pioneer in autonomous pharmacy technology, it enhances operational efficiency and patient safety across healthcare systems.
Omnicell reported Q1 2022 GAAP and non-GAAP revenues of $319 million, a 27% increase year-over-year. GAAP net income was $8 million ($0.17/share), down from $14 million ($0.30/share) in Q1 2021. Non-GAAP net income remained stable at $38 million ($0.83/share). The company launched the IVX Station, aimed at improving medication management through automation. For FY 2022, Omnicell anticipates revenues between $1.385 billion and $1.410 billion, with non-GAAP EPS projected between $3.85 and $4.05.